bioage initial public offering news

BioAge Labs, An Obesity Newcomer And Eli Lilly Partner, Rises On Upsized IPO

BioAge Labs stock rose Thursday on the company's upsized IPO — reflecting enthusiasm for its approach to obesity treatments.

Fast Company · 1d

BioAge Labs IPO: Stock price will be closely watched today as the obesity drug developer debuts on the Nasdaq

California-based biotech BioAge Labs will have its initial public offering of stock. The company is developing Azelaprag, a weight loss drug.

pharmaphorum · 1d

Obesity drug developer BioAge raises $198m in IPO

BioAge Labs has completed its upsized initial public offering (IPO), raising $198 million after increasing the number of shares on offer by 40%.

BioAge Labs Announces Pricing of Upsized Initial Public Offering

BioAge Labs, Inc. (“BioAge”) (Nasdaq: BIOA), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of ...

BioAge seeks nearly $200 million in initial public offering

BioAge Labs Inc., which has turned its aging diseases focus toward the hot area of obesity drugs, hopes to raise up to close ...

23h

BioAge valued at $758 mln in debut as investors bet on weight-loss drug frenzy

Shares of BioAge Labs opened 25% above their initial public offering price on Thursday in a strong debut for the weight-loss drug developer against the backdrop of surging investor enthusiasm.

RTW Biotech notes BioAge Labs' USD198 million initial public offering

(Alliance News) - RTW Biotech Opportunities Ltd on Friday noted that portfolio firm BioAge Labs Inc has completed a USD198 million initial public offering.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results